Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Jang Won Son (Son JW), Sungrae Kim (Kim S)
Diabetes Metab J. 2015;39(5):373-383.   Published online 2015 Oct 22     DOI: https://doi.org/10.4093/dmj.2015.39.5.373
Citations to this article as recorded by Crossref logo
Sodium-Glucose Cotransporter-2 Inhibitor Use is Associated with a Reduced Risk of Heart Failure Hospitalization in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus: A Real-World Study on a Diverse Urban Population
Weijia Li, Adarsh Katamreddy, Rachna Kataria, Merle L. Myerson, Cynthia C. Taub
Drugs - Real World Outcomes.2022; 9(1): 53.     CrossRef
Comparative Cardiovascular Outcomes of SGLT2 Inhibitors in Type 2 Diabetes Mellitus: A Network Meta-Analysis of Randomized Controlled Trials
Yu Jiang, Pingping Yang, Linghua Fu, Lizhe Sun, Wen Shen, Qinghua Wu
Frontiers in Endocrinology.2022;[Epub]     CrossRef
Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine,
Diabetes Care.2022; 45(4): 938.     CrossRef

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus

Eugene Han, Minyoung Lee, Yong-ho Lee, Hye Soon Kim, Byung-wan Lee, Bong-Soo Cha, Eun Seok Kang
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 4113.     CrossRef
Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL
Miki Imazu, Atsushi Nakano, Shin Ito, Toshimitsu Hamasaki, Masafumi Kitakaze
Cardiovascular Drugs and Therapy.2019; 33(3): 363.     CrossRef
Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study
N.H. Kim, J. Choi, N.H. Kim, K.M. Choi, S.H. Baik, J. Lee, S.G. Kim
Diabetes & Metabolism.2018; 44(4): 361.     CrossRef
Glucagon secretion determined by the RIA method is lower in patients with low left ventricular ejection fraction: The new glass study
Makoto Murata, Hitoshi Adachi, Taishuke Nakade, Shigeru Oshima
Diabetes Research and Clinical Practice.2018; 144: 260.     CrossRef
Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study
Yi-Hsuan Lin, Yu-Yao Huang, Yi-Ling Wu, Cheng-Wei Lin, Pei-Chun Chen, Chee Jen Chang, Sheng-Hwu Hsieh, Jui-Hung Sun, Szu-Tah Chen, Chia-Hung Lin
Diabetology & Metabolic Syndrome.2018;[Epub]     CrossRef
Postmeal increment in intact glucagon-like peptide 1 level, but not intact glucose-dependent insulinotropic polypeptide levels, is inversely associated with metabolic syndrome in patients with type 2 diabetes
Soyeon Yoo, Eun-Jin Yang, Sang Ah Lee, Gwanpyo Koh
Endocrine Research.2018; 43(1): 47.     CrossRef
Dipeptidyl Peptidase-4 Inhibitors and Heart Failure Exacerbation in the Veteran Population: An Observational Study
Michael R. Cobretti, Benjamin Bowman, Ted Grabarczyk, Emily Potter
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2018; 38(3): 334.     CrossRef
Effects of a Dipeptidyl Peptidase 4 Inhibitor Sitagliptin on Glycemic Control and Lipoprotein Metabolism in Patients with Type 2 Diabetes Mellitus (GLORIA Trial)
Daisaku Masuda, Takuya Kobayashi, Masami Sairyou, Hiroyuki Hanada, Tohru Ohama, Masahiro Koseki, Makoto Nishida, Norikazu Maeda, Shinji Kihara, Tatsuya Minami, Koji Yanagi, Yasushi Sakata, Shizuya Yamashita
Journal of Atherosclerosis and Thrombosis.2018; 25(6): 512.     CrossRef
Management of diabetes in older adults
G. Sesti, R. Antonelli Incalzi, E. Bonora, A. Consoli, A. Giaccari, S. Maggi, G. Paolisso, F. Purrello, G. Vendemiale, N. Ferrara
Nutrition, Metabolism and Cardiovascular Diseases.2018; 28(3): 206.     CrossRef
DPP4 inhibitors and cardiovascular outcomes: safety on heart failure
Chang Xia, Aditya Goud, Jason D’Souza, CHanukya Dahagam, Xiaoquan Rao, Sanjay Rajagopalan, Jixin Zhong
Heart Failure Reviews.2017; 22(3): 299.     CrossRef
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure
Yuliya Lytvyn, Petter Bjornstad, Jacob A. Udell, Julie A. Lovshin, David Z.I. Cherney
Circulation.2017; 136(17): 1643.     CrossRef
Antidiabetic medications use trends in an Andalusian region from 2001 to 2014
Rocío López-Sepúlveda, María Ángeles García Lirola, Esther Espínola García, Jose María Jurado Martínez, Salvadora Martín Sances, Sonia Anaya Ordóñez, José Cabeza Barrera
Primary Care Diabetes.2017; 11(3): 254.     CrossRef
The regulatory role of DPP4 in atherosclerotic disease
Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan, Jixin Zhong
Cardiovascular Diabetology.2017;[Epub]     CrossRef
Guidelines on the management of arterial hypertension and related comorbidities in Latin America
Journal of Hypertension.2017; 35(8): 1529.     CrossRef
Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo
Ildiko Lingvay
Endocrine Practice.2017; 23(7): 831.     CrossRef
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio
Masayuki Kaneko, Mamoru Narukawa
Annals of Pharmacotherapy.2017; 51(7): 570.     CrossRef
Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu
Scientific Reports.2017;[Epub]     CrossRef
High circulating plasma dipeptidyl peptidase- 4 levels in non-obese Asian Indians with type 2 diabetes correlate with fasting insulin and LDL-C levels, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes: a case–control
Shajith Anoop, Anoop Misra, Surya Prakash Bhatt, Seema Gulati, Ravindra Mohan Pandey, Harsh Mahajan
BMJ Open Diabetes Research & Care.2017; 5(1): bmjdrc-2017-000393.     CrossRef
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride
Kyeong Seon Park, SooHeon Kwak, Young Min Cho, Kyong Soo Park, Hak C Jang, Seong Yeon Kim, Hye Seung Jung
Journal of Diabetes Investigation.2017; 8(2): 218.     CrossRef
New peroral antidiabetic drugs and heart failure
Jana Jiráčková, Alena Šmahelová
Interní medicína pro praxi.2016; 18(2): 78.     CrossRef
Plasma DPP4 activity is associated with no-reflow and major bleeding events in Chinese PCI-treated STEMI patients
Jing Wei Li, Yun Dai Chen, Wei Ren Chen, Jing Jing, Jie Liu, Yong Qiang Yang
Scientific Reports.2016;[Epub]     CrossRef
Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study
Yi-Chih Hung, Che-Chen Lin, Wei-Lun Huang, Man-Ping Chang, Ching-Chu Chen
Scientific Reports.2016;[Epub]     CrossRef
Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up
Takashi Nakamura, Yoshitaka Iwanaga, Yuki Miyaji, Ryuji Nohara, Takao Ishimura, Shunichi Miyazaki
Cardiovascular Diabetology.2016;[Epub]     CrossRef
Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit
Ersilia M. DeFilippis, Michael M. Givertz
Current Heart Failure Reports.2016; 13(3): 111.     CrossRef
Transcriptomic alterations in the heart of non-obese type 2 diabetic Goto-Kakizaki rats
Márta Sárközy, Gergő Szűcs, Veronika Fekete, Márton Pipicz, Katalin Éder, Renáta Gáspár, Andrea Sója, Judit Pipis, Péter Ferdinandy, Csaba Csonka, Tamás Csont
Cardiovascular Diabetology.2016;[Epub]     CrossRef